Abstract
Background: Conventional and biologic disease-modifying anti-rheumatic drugs (DMARDs) may complicate the wound healing process in patients with concomitant autoimmune disease by interfering with the inflammatory phase of healing. The purpose of this study was to evaluate the wound healing outcomes in patients at our tertiary wound center with autoimmune disease taking prescribed DMARDs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
